Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
46 participants
INTERVENTIONAL
2021-12-08
2022-09-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Nefopam in Breast Cancer Surgery
NCT02949310
Effects of Continuous Infusion of Intravenous Nefopam on Postoperative Pain and Opioid Consumption After VATS
NCT04450355
The Preemptive Analgesic Efficacy of Nefopam
NCT02561468
Postoperative Analgesic Effect of Nefopam
NCT02561494
A Comparison of Nefopam-propacetamol Combination and Propacetamol for Postoperative Quality of Recovery After Laparoscopic Nephrectomy
NCT01833728
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
Nefopam will not be administered in this group.
No interventions assigned to this group
nefopam group
Intravenous nefopam 20 mg will be administered twice, immediately after induction of anesthesia and at the end of surgery.
Nefopam
Nefopam 20 mg is mixed to 100 mL of normal saline, and is infused intravenously over 15 minutes.
20 mg of nefopam is administered intravenously for two times, after induction and at the end of surgery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nefopam
Nefopam 20 mg is mixed to 100 mL of normal saline, and is infused intravenously over 15 minutes.
20 mg of nefopam is administered intravenously for two times, after induction and at the end of surgery.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Society of Anesthesiologists physical grade I, II, III
* patient aged from 18 years old
Exclusion Criteria
* renal insufficiency
* liver insufficiency
* myocardial infarction
* glaucoma
* pregnant and lactating women at the time of surgery
* patient who did not consent to the use of patient-controlled analgesia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kangbuk Samsung Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eunah Cho, MD
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eunah Cho
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ki HS, Shim JG, Choi HK, Ryu KH, Kang DY, Park J, Ahn JH, Lee SH, Cho EA. Nefopam as a multimodal analgesia in thoracoscopic surgery: a randomized controlled trial. J Thorac Dis. 2024 Jun 30;16(6):3644-3654. doi: 10.21037/jtd-24-30. Epub 2024 Jun 12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NEVATS2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.